Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: journal – Reuters
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING (Reuters) – A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emir…
-
Noosa News16 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News22 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business21 hours agoAre BHP shares are buy after its results?
-
Business13 hours agoWhere next for the CBA share price?